Saturday 17 October 2026
Export SNDX’s income statement to Excel — free account
Syndax Pharmaceuticals, Inc.
SNDX Healthcare Biotechnology
Syndax Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $172.4 million, up 627.8% from fiscal 2024. In the quarter to June 2026, revenue grew 91.8%, EPS grew 33.7%, free cash flow grew 65.5% and total debt rose 71.0%, each against the same quarter a year earlier.
12.88
0.77
−5.64%
Follow SNDX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
7.72 | 9.49 | 10.56 | 11.95 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(64.26) | (40.95) | (26.19) | (18.90) | |
P/B ratio |
128.84 | 49.53 | 28.16 | 11.55 | |
Price to Tangible BV |
128.84 | 49.53 | 28.16 | 11.55 | |
EV/Sales |
7.94 | 9.52 | 10.29 | 10.96 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(9.07) | (7.43) | (5.49) | (3.93) | |
EV/FCF |
(9.06) | (7.43) | (5.49) | (2.57) | |
Quick Ratio |
6.26 | 4.88 | 4.01 | 4.34 | |
Current Ratio |
6.77 | 5.47 | 4.40 | 4.64 | |
Net Debt/EBITDA |
(0.84) | 0.50 | 1.09 | 1.84 | |
Debt/Assets |
83.58% | 72.77% | 64.92% | 62.33% | |
Debt/Equity |
38.95 | 8.26 | 5.32 | 2.98 | |
Asset Turnover |
0.39 | 0.39 | 0.27 | 0.23 | |
Operating CF/Net income |
0.61 | 1.18 | 1.02 | 1.16 | |
Capex/Depreciation |
0.08 | 0.00 | 0.04 | 0.06 | |
Interest Coverage |
(3.16) | (2.89) | (5.75) | (6.93) | |
Research and Development Expense of Revenue |
93.47% | 90.72% | 114.84% | 122.69% | |
Selling, General and Administrative Expense of Revenue |
57.07% | 57.95% | 72.91% | 97.92% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
19.25% | 18.58% | 16.43% | 26.34% | |
Graham Net Nets |
(0.01) | 0.02 | 0.03 | 0.07 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(11.48%) | (11.94%) | (15.66%) | (23.46%) | |
Free Cash Flow Yield |
(11.35%) | (13.49%) | (17.74%) | (35.66%) | |
Revenue per Share |
0.82 | 0.74 | 0.79 | 0.53 | |
Operating CF per Share |
(0.34) | (0.57) | (0.80) | (0.81) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.34) | (0.57) | (0.80) | (0.82) | |
Cash per Share |
6.23 | 4.09 | 4.78 | 5.24 | |
Shareholders Equity per Share |
0.17 | 0.47 | 0.75 | 1.33 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.17 | 0.47 | 0.75 | 1.33 | |
Free Cash Flow |
(30.31) | (50.34) | (69.54) | (70.67) | |
Working Capital |
575.36 | 385.00 | 407.97 | 415.64 | |
Capital Expenditures |
(0.04) | — | (0.06) | (0.13) | |
Net Current Asset Value |
(13.51) | 40.13 | 63.01 | 93.47 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
52.76 | 39.10 | 39.69 | 22.32 | |
Average Payables |
11.11 | 10.45 | 14.10 | 9.36 | |
Average Inventory |
25.43 | 19.81 | 16.56 | — | |
Average Assets |
649.90 | 556.69 | 627.26 | 488.80 | |
Average Common Equity |
86.26 | 128.34 | 176.38 | 240.93 |
Columns are period end dates